Verastem shares rise 3.92% in after-hours after positive Phase 1 FRAME study results for avutometinib and defactinib combination therapy.

Verastem, Inc. surged 3.92% in after-hours trading, following the publication of Phase 1 FRAME study results in Nature Medicine, showing a 42.3% overall response rate and a median progression-free survival of 20.1 months for low-grade serous ovarian cancer patients treated with avutometinib and defactinib. The response rate increased to 58.3% for KRAS-mutated patients, with a median progression-free survival of 30.8 months.